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Horses with equine infectious anemia virus (EIAV) have episodes of viremia and disease; however, most eventually
become inapparent carriers. A possible mechanism of control is cytotoxic T lymphocytes (CTL). To evaluate CTL in inapparent
carriers with low viral loads, peripheral blood mononuclear cells (PBMC) were stimulated in vitro with autologous EIAV-
infected PBMC and human IL-2 to detect memory CTL (CTLm). In initial studies, three carriers had CTLm and one of these
had low-level effector CTL (CTLe). The CTLm were restricted by equine lymphocyte alloantigen-A (ELA-A) locus encoded
MHC class I molecules on autologous equine kidney (EK) target cells. In addition, EK cells did not express MHC class II
molecules. The CTLm frequency in PBMC from five inapparent carriers infected for 22 to 50 months was determined by
limiting dilution analysis. PBMC were diluted, stimulated, and tested on EK cell targets infected with EIAV and recombinant
vaccinia viruses expressing EIAV Env or Gag/Pr proteins. All five carriers had CTLm to EIAV-infected targets, while four
had CTLm to targets expressing Env and four had CTLm to targets expressing Gag/Pr proteins. The CTLm frequency range
was 60 to 468 per 106 PBMC to EIAV-infected targets, 4 to 286 to Env-expressing targets, and 25 to 190 to Gag/Pr-
expressing targets. These results should facilitate the identification of epitopes recognized by predominant CTLm from
horses controlling a lentivirus infection. q 1997 Academic Press
of EIAV to noninfected horses (Coggins et al., 1972; IsselINTRODUCTION
et al., 1982; Coggins, 1984).
The mechanisms carrier horses use to control EIAVEquine infectious anemia virus (EIAV) causes disease
are not known. Infected horses control the initial plasmain horses with some distinctive features when compared
viremia by specific immune responses since youngwith other lentiviral infections of humans and animals.
horses with severe combined immunodeficiency fail toThere is an episode of plasma viremia with associated
terminate initial viremia, while immunocompetent youngfever, thrombocytopenia, and anemia within 1 to 4 weeks
horses terminate the initial viremia (Perryman et al.,after infection which lasts several days (Kono, 1969; Cog-
1988). Whether antibody or other lymphocyte responsesgins et al., 1972). Most horses infected with either wild-
are involved is unknown because young horses with se-type strains (Kono, 1969) or strains derived from the tis-
vere combined immunodeficiency lack functional T and Bsue culture-adapted prototype strain (Orrego et al., 1982;
lymphocytes (McGuire et al., 1975). Antibodies mediatingO’Rourke et al., 1988) terminate the initial disease epi-
antibody-dependent cellular cytotoxicity (ADCC) do notsode, although some horses infected with wild-type
appear to be involved in virus control because thesestrains may die during the initial disease. Surviving
antibodies cannot be demonstrated in sera from infectedhorses usually have episodes of viremia and clinical dis-
horses (Fujimiya et al., 1979; Tschetter et al., 1997). Neu-ease interspersed with quiescent periods of one to sev-
tralizing antibodies are detected following infection witheral weeks during the first few months after infection
EIAV (Kono, 1969) and the specificity of the neutralizing(Kono, 1969; Orrego et al., 1982; O’Rourke et al., 1988).
antibody response broadens during persistent infectionThen, the disease episodes become less frequent until
(O’Rourke et al., 1989; Rwambo et al., 1990). The delayedthe horses are inapparent carriers with low virus loads
appearance of type-specific neutralizing antibodies after(Kono, 1969; Issel et al., 1982; Coggins, 1984; Langemeier
the termination of viremia by that virus type (Carpenteret al., 1996). Carriers live for years and can be detected
et al., 1987; O’Rourke et al., 1989; Rwambo et al., 1990)by antibodies to EIAV proteins and by blood transmission
and the antigenic variation of epitopes recognized by
neutralizing antibody (Kono et al., 1973b; Montelaro et
al., 1984) may limit the effectiveness of neutralizing anti-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (509) 335-8529. E-mail: mcguiret@vetmed.wsu.edu. body in EIAV control. Nevertheless, a protective role for
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TABLE 1antibody is indicated by passive transfer of plasma con-
taining neutralizing antibodies from EIAV-infected to Frequency of CTLm in PBMC from EIAV Carrier Horses
noninfected horses (Rushlow et al., 1990). This plasma to EIAV-Infected EK Target Cells
transfer did not prevent infection of the recipient horses
Horse number Months after CTLm per 106 PBMCfollowing EIAV challenge, but the transfer delayed sero-
(ELA-A haplotypea) EIAV infection (95% confidence interval)conversion and in one case delayed clinical disease
(Rushlow et al., 1990). H-507 (A7/W11) 50 400 (299–535)
Support for mechanisms of immune control other than H-521 (A1/W11) 41 468 (314–696)
H-525 (A3/A9) 37 60 (39–90)antibodies include observations of EIAV-infected horses
H-529 (A1/A5) 22 173 (127–234)(Kono et al., 1973a) and vaccinated horses (Issel et al.,
H-532 (A6/A9) 22 362 (271–484)1992) resisting challenge in the absence of detectable
neutralizing antibody. Active immune responses are im- a The equine lymphocyte alloantigen (ELA-A) haplotypes were identi-
plicated in EIAV control by carrier horses since either fied by microcytotoxicity assays using described serologic reagents
(Bailey, 1980, 1983).corticosteroids or cyclophosphamide causes plasma vi-
remia within 1 to 2 weeks after treatment (Kono et al.,
1976; Tumas et al., 1994). The virus in plasma following
nies) were used in these experiments. EIAVwsu5 is a celltreatment is a neutralizing antibody escape-variant ap-
culture-adapted strain isolated after three sequentialpearing while neutralizing antibody to the variant used for
passages of the prototype strain (Malmquist et al.,infection is still detectable (Kono et al., 1976). Therefore,
1973) in horses and the predominant virus type se-neutralizing antibody in plasma probably controls viremia
lected by three limiting dilutions on EK cell culturesby recognized EIAV variants. New variants, and virus
(O’Rourke et al., 1988). EIAVwsu5 causes viremia andreplication to generate new variants, may be controlled
clinical disease in young horses (Perryman et al., 1988)by T lymphocyte responses including cytotoxic T lympho-
and ponies (O’Rourke et al., 1988; McGuire et al., 1994b).cytes (CTL).
Infection of H-507, H-521, and H-525 and the method ofSince our long-term goal is to clarify the mechanisms
obtaining autologous EK cells from kidney biopsies forthat inapparent carrier horses use to control EIAV replica-
CTL target cells have been described (McGuire et al.,tion, we are investigating the hypothesis that MHC class
1994b). Similar procedures were used to obtain EK cellsI-restricted virus-specific CD8/ CTL are involved. To this
from 18 noninfected horses and to infect 2 of these, H-end, CTL meeting these criteria were previously demon-
529 and H-532, with 109 50% tissue culture infectivestrated in peripheral blood mononuclear cells (PBMC)
doses (TCID50) of EIAVwsu5 . Except for H-507 (McGuire etcoincident with the initial viremic episode in infected
al., 1994b), the other 4 infected horses had at least onehorses (McGuire et al., 1994b). These were effector CTL
episode of fever, viremia, and thrombocytopenia. The(CTLe) not requiring in vitro stimulation and were present
mean platelet count for 16 noninfected horses (mixedfor at least 3 months after infection. Thereafter, CTLe
breed ponies) in this study was 214,855/ml and thrombo-levels in PBMC declined (unpublished observation). Re-
cytopenia was defined as 100,800/ml which was 2 SDcently, EIAV-specific memory CTL (CTLm) were demon-
below the mean. Equine lymphocyte alloantigen-A (ELA-strated in PBMC from inapparent carriers using as target
A) locus encoded MHC class I proteins on lymphocytescells pokeweed mitogen-stimulated PBMC infected with
(Table 1) were identified by microcytotoxicity assays us-recombinant vaccinia viruses expressing EIAV proteins
ing described serologic reagents (Bailey, 1980, 1983).(Hammond et al., 1997). One way to further evaluate the
The ELA-A locus is the only well-defined class I locus inrole of CTL in controlling viral load is to induce CTL in
the horse (Lazary et al., 1988).horses by immunization and to evaluate the effects of
EIAV challenge. Since epitopes recognized by predomi-
nant CTLm from inapparent carriers may induce the req- Assays for CTLe and CTLm
uisite response for evaluation, experiments were done
to demonstrate CTLm in carriers to equine kidney (EK) To measure CTLe, freshly isolated, nonstimulated
PBMC (Wyatt et al., 1988) were evaluated using a 51Crcell targets expressing EIAV proteins, to further indicate
that the CTLm were MHC class I-restricted, and to do release assay with a 17-hr incubation period (McGuire
et al., 1994b). The formula, % specific lysis  [(E 0 S)/limiting dilution analysis to determine CTLm frequency to
EIAV-infected target cells and to target cells expressing (M 0 S)] 1 100 (Siliciano et al., 1985) was used, where
E is the mean of six test wells, S is the mean spontaneouseither Env or Gag/Pr proteins.
release from six target cell wells without effector cells,
MATERIALS AND METHODS
and M is the mean maximal release from six target cell
EIAV-infected and control horses wells with 2% Triton X-100 in distilled water. The standard
error (SE) of percentage specific lysis was calculatedFive horses (mixed breed ponies) infected with
EIAVwsu5 and 16 noninfected horses (mixed breed po- using a formula that accounts for the variability of E, S,
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and M (Siliciano et al., 1985). Only assays with a sponta- 6 days. Cells from each of the 24 wells were resuspended
neous lysis of 30% were used. and transferred to a well of EK target cells labeled with
To detect CTLm, 106 PBMC were stimulated in 24-well 51Cr (McGuire et al., 1994b). The plates were incubated
plates with each well containing 1 ml of RPMI 1640 with at 377 for 17 hr and centrifuged for 5 min at 200 g, and
10% fetal calf serum, 5 1 1005 M 2-mercaptoethanol, and 0.1 ml of supernatant was removed to determine 51Cr
20 mM HEPES plus 106 irradiated stimulator PBMC which release.
contained EIAVwsu5-infected monocytes. These stimulator
cells were prepared by exposing 108 autologous PBMC
Analysis of limiting dilution assay datato 3000 rad of gamma irradiation, mixing with 2 ml con-
taining 106 TCID50/ml EIAVwsu5 , and incubating at 377 for
Each of the 24 wells of the limiting dilution assay was1 hr. After 7 days of stimulation, viable lymphocytes were
scored as positive or negative based on whether theisolated using Histopaque and restimulated in a 24-well
51Cr release exceeded a specific lysis threshold. Theplate with each well containing 4 1 105 isolated lympho-
threshold was calculated as the mean spontaneous re-cytes and 106 stimulator cells in 1 ml of the above me-
lease / 10% of the specific release (Carmichael et al.,dium plus 20 units/ml recombinant human IL-2 (Gibco
1993). For each target cell type, the mean spontaneousBRL, Grand Island, NY), which stimulates equine lympho-
release from 12 target cell wells without effector cellscytes (Magnuson et al., 1987). Restimulation was done
and the mean maximal release from 12 target cell wellsevery 3–4 days and lymphocytes stimulated for 14 to 20
with 2% Triton X-100 in distilled water were determined,days were evaluated for CTL activity using the same
and the specific release was calculated as the meanassay procedure and calculations described for CTLe.
maximal release minus the mean spontaneous release.
The wells without CTLm and those with at least oneCTLm frequency in PBMC from carrier horses to
EIAV-specific CTLm had bimodal distributions of 51Cr re-EIAV-infected targets
lease that were consistently differentiated using the de-
scribed threshold (Carmichael et al., 1993). The limitingQuantitative estimates of CTLm were derived by lim-
dilution data were analyzed by calculating the frequencyiting dilution analysis of PBMC that were first diluted and
of CTL and a 95% confidence limit using the maximumthen stimulated (Carmichael et al., 1993). Dilutions of
likelihood method and testing the goodness of fit of thePBMC were made in DMEM with 15% fetal calf serum
data with the Poisson model by calculating x2 (Fazekasand 15% calf serum (DMEM/) so that 0.1 ml containing
10,000, 5000, 2500, and 1250 PBMC could be added to De St Groth, 1982).
wells of a 96-well (round-bottom) plate. Three sets of 24
wells for each dilution were stimulated before assaying
CTLm killing and CTLm frequency using cell targetsfor CTL activity on three different target cells including
expressing EIAV Env and Gag/Pr proteinsEIAVwsu5-infected autologous and ELA-A mismatched EK
cells and noninfected autologous EK cells. Stimulation
Before using EK cell targets infected with recombinantof PBMC was done in each well by adding EIAVwsu5-
vaccinia viruses expressing Env or Gag/Pr proteins ininfected monocytes. The monocytes were isolated using
limiting dilution assays for CTLm, these target cells weregelatin and autologous plasma-coated flasks (Freundlich
evaluated with stimulated PBMC in CTL assays. Oneand Avdalovic, 1983; Maury, 1994). Briefly, 2 1 107 PBMC
recombinant vaccinia virus was used, VGag/Pr), whichirradiated with 3000 rad in 15 ml of RPMI 1640 with
expresses the EIAVwsu5 55-kDa Gag precursor and an20% calf serum were added to 75-cm2 coated flasks and
82-kDa Gag/Pol fusion protein including protease (PR),incubated for 1 hr at 377, and non-adherent cells were
which are processed into subviral particles containingremoved by washing three times with HBSS warmed to
p26 (McGuire et al., 1994a). Another recombinant virus377. Adherent monocytes were infected by adding 6 ml/
was VEnv2, which expresses the EIAVwsu5 Env precursorflask containing 105.5 TCID50/ml EIAVwsu5 , incubating at
that is cleaved by cellular proteases into SU and TM377 for 1 hr, and then washing once with RPMI with 20%
proteins (McGuire et al., 1994b). A control recombinantcalf serum. Infected monocytes were removed by adding
virus, VSC11, which expresses beta-galactosidase, was5 ml/flask HBSS with 10 mM EDTA plus 5 ml/flask RPMI
also used, but EIAV proteins were not used (McGuire etwith 20% calf serum and incubating at 377 for 15 min.
al., 1994b). Finally, recombinant vaccinia virus-infectedFollowing centrifugation for 10 min at 200 g and washing
EK target cells expressing EIAV proteins were used toonce with DMEM/, 105 infected monocytes in 0.1 ml were
determine the frequency of CTLm in PBMC from fiveadded to each well of effector cells and incubated for 6
carrier horses infected for 22 to 50 months. The PBMCdays in a humidity chamber at 377 with 5% CO2 . Then,
were diluted from 32,000 to 4000/well and stimulated,0.1 ml of medium was removed from each well, replaced
and limiting dilution analysis of CTL activity was donewith 0.1 ml of DMEM/ containing 40 units/ml of recombi-
nant human IL-2 (Gibco BRL), and incubated for another as described in the two preceding paragraphs.
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RESULTS ure to kill EIAV-infected target cells from other horses
(mismatched) and elimination of CTL activity by removalCTLe and CTLm in PBMC from EIAV-infected horses
of CD8/ T lymphocytes with a MAb to equine CD8Prior to assays to measure CTL in PBMC, the five
(McGuire et al., 1994b). The role of MHC class I-re-EIAV-infected horses were evaluated for 5 weeks by tak-
stricted killing of EIAV-infected EK target cells was impli-ing daily body temperatures and determining platelet
cated in the current paper by demonstrating that thesecounts, packed cell volumes, and plasma viremia three
cells expressed MHC class I, but not MHC class II mole-times per week. During this period, three horses (H-507,
cules. Three MAbs (Davis et al., 1987; Kydd et al., 1994)H-521, and H-525, infected for 34, 24, and 22 months,
reacting with monomorphic determinants of equine MHCrespectively) lacked plasma viremia detectable by assay
class I (H58A, PT85A, and B5C) stained 97.4 to 98.4% ofon EK cell cultures (O’Rourke et al., 1988). They also
the EK cells by fluorescent flow cytometry while threelacked fever, anemia, and thrombocytopenia and were
MAbs reacting with monomorphic determinants ofconsidered carriers. The two other horses (H-529 and H-
equine MHC class II (H34A, TH14B, and TH81A) bound532), which were infected for only 6 months, were not
2.4 to 4.6% of EK cells. Isotype control MAbs bound 1.4considered carriers as both had low-level, but detectable,
and 2.5% of EK cells.viremia (101.3 and 101.5 TCID50%/ml, respectively). These
Killing of infected EK target cells was further confirmedtwo horses had no fever, thrombocytopenia, or anemia
to be MHC class-I restricted by evaluating killing of targetexcept for H-529, which had thrombocytopenia on one
cells from horses of known ELA-A types by stimulatedoccasion.
PBMC from H-532. These PBMC caused significant lysisTo measure CTLe, freshly isolated, nonstimulated
of EIAVwsu5-infected autologous EK target cells and ofPBMC were used in the 51Cr release assay. PBMC from
infected EK target cells from horses with one matchedcarriers H-507 and H-521 did not have CTLe as neither
ELA-A haplotype, but not of infected target cells fromcaused significant lysis of autologous EIAVwsu5-infected
horses with a mismatch of both ELA-A haplotypes (Fig.EK target at 10:1 and 50:1 effector to target (E:T) cell
2). The percentage specific lysis of mismatched, but in-ratios (Fig. 1). However, PBMC from carrier H-525 at a
fected, target cells was greater than uninfected target50:1 E:T cell ratio had low-level CTLe causing significant
cells when A7/w11 and A1/w11 targets were used; how-lysis (12.1%) of infected EK targets (Fig. 1). The percent-
ever, the percentage lysis did not exceed that occurringage specific lysis of autologous infected EK target cells
with uninfected autologous cells and was not consideredwas considered significant when it exceeded the specific
significant (see the definition in the legend to Fig. 2). Thelysis of both autologous noninfected EK cells and ELA-
highest level of EIAV-specific killing occurred when theA-mismatched, EIAVwsu5-infected EK cell targets by three
infected target cells were autologous and killing of in-times the standard error. PBMC from H-529, one of the
fected target cells with one matched ELA-A haplotypetwo horses with low-level viremia, caused very low, but
was about 50% less (Fig. 2).significant, lysis (8.6% at a 50:1 E:T cell ratio) of infected
targets (Fig. 1). PBMC from H-532, the other horse with
CTLm frequency in carrier horse PBMC to EIAV-low-level viremia, had 13.7 and 22.0% lysis at E:T ratios
infected targetsof 10:1 and 50:1, respectively (Fig. 1).
CTLm were measured following in vitro stimulation of The number of CTLm to EIAV-infected targets was de-
PBMC, and PBMC from carriers (H-507, 521, and 525) termined by limiting dilution analysis of PBMC from the
caused significant lysis of autologous EIAVwsu5-infected same five infected horses described above, but it was
EK target cells at E:T cell ratios of 5:1 and 25:1 with lysis done 16 months later. The horses were now infected for
at the 25:1 cell ratio ranging from 24.0 to 34.9% (Fig. 22 to 50 months and all were considered carriers as
1). Stimulated PBMC from the two horses with low-level clinical disease (anemia and thrombocytopenia) was not
viremia also caused significant lysis of autologous in- detected for 5 weeks and viremia was not detected by
fected targets at both E:T cell ratios with 25.8% for H-529 assay on EK cell cultures during the subsequent 4 weeks.
and 54.8% for H-532 at the 25:1 E:T cell ratio (Fig. 1). The frequency of CTLm in the diluted and stimulated
Expression of MHC class I on EK target cells and PBMC from these carrier horses to EIAVwsu5-infected au-
restriction of CTL killing by ELA-A tologous EK target cells ranged between 60 and 468 per
106 PBMC (Table 1) with a mean frequency of 293 perPrevious evidence that EIAV-specific CTLe from in-
fected horses were MHC class I-restricted included fail- 106 PBMC. There was no lysis in wells containing either
FIG. 1. Evaluation of CTL-specific lysis by nonstimulated (NS) and stimulated (S) PBMC from EIAV-infected horses. Each panel contains
results from PBMC from each of five horses including three carrier horses (H-507, 521, and 525) and two horses with low-level viremia (H-529
and 532). Target cells were noninfected autologous EK cells (crosshatched bars in each panel) and EIAVwsu5-infected autologous (IEK) cells
(black bars), plus noninfected ELA-A-mismatched EK cells (white bars) and infected ELA-A-mismatched (IEK) cells (diagonally striped bars).
The effector to target cell ratios were 10:1 and 50:1 for NS PBMC and 5:1 and 25:1 for S PBMC. Significant killing is detailed under Results.
Vertical lines on columns are SEs.
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CTLm killing of target cells expressing Env or Gag/Pr
proteins
Prior to using EK cell targets infected with recombinant
vaccinia viruses expressing EIAV proteins in limiting dilu-
tion assays, killing of these targets by stimulated PBMC
from H-532 was evaluated. These PBMC caused signifi-
cant lysis of autologous EK target cells infected with
recombinant vaccinia viruses expressing either Env or
Gag/Pr proteins when compared to controls of nonin-
fected autologous EK target cells and autologous EK tar-
get cells infected with VSC11 (Fig. 3). The specific lysis
at an E:T cell ratio of 10:1 was similar with target cells
expressing Gag/Pr or Env proteins, but both targets were
lysed less than EIAVwsu5-infected target cells (Fig. 3). The
relative efficiency of EIAV protein epitope expression by
MHC class I molecules on EK target cells infected with
either EIAV or recombinant vaccinia viruses expressing
EIAV proteins is unknown. The demonstration of CTLm
to both Env and Gag/Pr protein epitopes indicated that
cell targets expressing these epitopes were suitable for
FIG. 2. Comparison of CTL-specific lysis by stimulated PBMC from use in limiting dilution analysis.
EIAV-infected horse H-532 when EK target cells were autologous (A6/
A9), ELA-A-matched at one haplotype (A5/A6, A3/A9), or ELA-A-mis-
CTLm frequency in carrier horse PBMC to targetsmatched (A5/A8, A7/W11, A1/W11). The E:T cell ratio in this experiment
expressing Env or Gag/Pr proteinswas 20:1. The clear columns are noninfected EK target cells and the
solid columns are EIAVwsu5-infected EK target cells. Vertical lines on The number of CTLm recognizing either target cells
columns are SEs. Asterisks above the columns indicate significant
expressing Env proteins or Gag/Pr proteins was deter-specific lysis that was three SEs greater than that occurring with
either the autologous noninfected EK cells or the ELA-A-mismatched,
EIAVwsu5-infected EK cell targets.
noninfected autologous or EIAVwsu5-infected, ELA-A-mis-
matched EK target cells, indicating that 5 CTL per 106
PBMC recognized these targets. The 5 CTL per 106
PBMC is based on negative results in 24 wells containing
the maximum number of 10,000 PBMC tested/well. As a
control, the CTLm frequency in PBMC from three non-
EIAV-infected horses was evaluated and PBMC from two
of these noninfected horses had no detectable CTL to
EIAVwsu5-infected or control EK cell targets. However,
PBMC from a third noninfected horse (H-504) had 155
and 178 CTLm per 106 PBMC in two experiments with
autologous EIAV-infected EK cell targets. There were 31
and 5 CTL per 106 PBMC with autologous noninfected
EK cell targets and 5 CTL per 106 with EIAV-infected
ELA-A mismatched EK cell targets. In a separate limiting
dilution assay run as described in a subsequent section,
stimulated H-504 PBMC did not lyse EK cells expressing
recombinant Env or Gag/Pr proteins. In addition, nonstim-
FIG. 3. CTL-specific lysis by stimulated PBMC from EIAV-infected
ulated H-504 PBMC did not lyse EIAV-infected autolo- horse H-532 when EK target cells were infected with EIAVwsu5 or
gous EK target cells. To determine if results from H-504 recombinant vaccinia viruses expressing no EIAV protein (VSC11),
Env proteins (VEnv2), or Gag and protease proteins (VGag/Pr). Thewere common, stimulated PBMC from an additional 13
solid columns are autologous EK target cells and the clear columnsnoninfected horses were examined for CTLm to autolo-
are ELA-A-mismatched EK target cells. Vertical lines on columns aregous EIAV-infected EK target cells, and none were found.
SEs. Asterisks above the columns indicate significant specific lysis
From this result, it was concluded that the killing of EIAV- that was three SEs greater than that occurring with autologous nonin-
infected target cells by one uninfected horse, H-504, was fected EK target cells, ELA-A-mismatched EIAVwsu5-infected EK target
cells, and VSC11-infected target cells.uncommon and probably of little significance.
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TABLE 2 with CTLm from two horses with low-level viremia. There
was low-level, but significant, specific lysis by CTLe inFrequency of CTLm per 106 PBMC (95% Confidence Interval)
unstimulated PBMC from one of three EIAV carriers. ThisSpecific for EIAV Env and Gag/Pr Proteins
latter observation was similar to the detection of in vivo-
EK target cells infected with recombinant activated CTL in a person infected with HIV-1 for 15 years
vaccinia viruses and with very low viral load (Harrer et al., 1996). In the
Horse
case of the carrier horse, the presence of activated CTLnumber VSC11 controla VEnv2b VGag/Pr c
may result from low-level virus production undetectable
H-507 2 89 (66–118) 59 (44–80) by in vitro assays for infectious virus used here, yet per-
H-521 13 286 (205–400) 190 (140–259) haps detectable by RT-PCR assay (Langemeier et al.,
H-525 2 4 (2–9) 2 1996). Lentiviral particles in the blood, whether infectious
H-529 2 2 25 (17–36)
or noninfectious, indicate viral protein expression byH-532 2 38 (25–59) 37 (24–58)
cells and could provide an antigen stimulus in EIAV carri-
a Recombinant vaccinia virus expressing b-galactosidase, but no ers both for the CTLe demonstrated in the current paper
EIAV proteins. and for the previously described persistence of antibody
b Recombinant vaccinia virus expressing EIAV Env proteins SU and to EIAV proteins (Hammond et al., 1997). It was con-
TM.
cluded from these results that low-level CTLe could occurc Recombinant vaccinia virus expressing EIAV Gag proteins and pro-
in a carrier horse and that CTLm to EIAV-infected EKtease.
target cells were easily demonstrated in the three carrier
horses evaluated. Moreover, CTLm from a carrier horse
mined by limiting dilution analysis of PBMC from the five recognized epitopes from EIAV Env and Gag/Pr proteins
carrier horses. Four of five carriers had CTLm which as previously described for CTLe from recently infected
killed autologous EK cells expressing Env proteins and horses (McGuire et al., 1994b; Hammond et al., 1997) and
the range was 4 to 286 per 106 PBMC. A fifth carrier had for CTLm from carriers (Hammond et al., 1997), allowing
2 per 106 PBMC (Table 2). The 2 CTL per 106 PBMC target cells expressing these proteins to be used in lim-
is based on negative results in 24 wells containing the iting dilution analysis.
maximum number of 32,000 PBMC tested/well. The The CTLm lysis of EK target cells infected with EIAV
CTLm per 106 PBMC from four of the five carriers killing or expressing EIAV proteins was indicated to be MHC
autologous EK cells expressing Gag/Pr proteins was 25 class I-restricted by demonstrating that EK target cells
to 190, while the fifth carrier had 2 (Table 2). The three expressed MHC class I molecules, but not class II mole-
horses with the highest number of CTLm to EIAV-infected cules. The CTL-specific lysis of EK target cells was as
cells had the highest number of CTLm to both Env- and high as 54.8% (Fig. 1) and occurred in the absence of
Gag/Pr-expressing target cells (Tables 1 and 2). The MHC class II molecules. This indication was further sup-
horse with the lowest number of CTLm to EIAV-infected ported by demonstrating lysis of autologous EIAV-in-
target cells (H-525) had barely detectable CTLm to Env fected target cells and of infected target cells from horses
and Gag/Pr proteins. Four carriers had 2 CTLm per 106 with one matched ELA-A molecule, but not of infected
PBMC when tested on autologous target cells infected target cells from horses with a mismatch of both ELA-A
with the control recombinant vaccinia virus (VSC11) ex- molecules. The data in this paper suggest that the killing
pressing b-galactosidase while the fifth (H-521) had 13 observed was MHC class I-restricted, but do not provide
CTLm/106 PBMC when tested on this latter target cell direct proof. Previous work demonstrated that depleting
(Table 2). Furthermore, 2 CTLm per 106 PBMC were CD8/ T lymphocytes removed EIAV-specific CTLe from
detected in PBMC from the five carrier horses when ELA- PBMC from horses with recent EIAV infections (McGuire
A-mismatched EK cells expressing either Env or Gag/Pr et al., 1994b). Studies of EIAV-specific CTLm in PBMC
were evaluated. In only one horse (H-521) did the sum from inapparent carriers using pokeweed mitogen-stimu-
of CTLm to Env and Gag/Pr proteins nearly equal the lated PBMC targets infected with recombinant vaccinia
number of CTLm to EIAV-infected target cells. In the other viruses expressing EIAV proteins demonstrated both
four carriers, this sum was less than the number reacting MHC class I- and MHC class II-restricted killing, although
to EIAV-infected EK cells. the MHC class I killing was greater (Hammond et al.,
1997). In addition, MHC class I restriction occurs with
equine CTL killing of equine herpes virus I-infected targetDISCUSSION
cells (Allen et al., 1995).
The frequency of CTLm in PBMC from carrier horsesThe initial CTL assays in this study evaluated both
PBMC stimulated in vitro with EIAV-infected autologous to EIAV-infected EK target cells ranged from 60 to 468
per 106 PBMC. These values are similar to some reportedPBMC and nonstimulated PBMC. In vitro stimulation of
PBMC from three carrier horses resulted in high levels for people infected with HIV-1 (Carmichael et al., 1993),
but are lower than those reported for a defined group ofof specific lysis by CTLm. Similar results were obtained
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